Table 1 Characteristics and Clinical Outcomes of patient.

From: Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer

Patient characteristic

Total

Number

%

Total patient

1004

  

Median age(range)

1004

58(26–82)

 

Age

1004

  

 ≤58

 

518

51.6

 >58

 

486

48.4

Gender

1004

  

 Male

 

706

70.3

 Female

 

298

29.7

TNM Stage

999

  

 IIIA

 

81

8.1

 IIIB

 

293

29.3

 IV

 

625

62.6

ECOG PS

990

  

 0–1

 

904

91.3

 2

 

86

8.7

Histological Type

1004

  

 Adenocarcinoma

 

632

62.9

 Squamous Cell Carcinoma

 

221

22.0

 Adenosquamocarcinoma

 

20

2.0

Othersa

 

131

13.1

Smoking Statusb

1000

  

 Never smoker

 

425

42.5

 Ever smoker

 

575

57.5

Chemotherapy Regimens

1004

  

 Platinum-navelbine

 

316

31.5

 Platinum-gemcitabine

 

239

23.8

 Platinum-paclitaxel

 

313

31.1

 Platinum-docetaxel

 

87

8.7

Others platinum combinations

 

49

4.9

Objective Response

975

  

 CR

 

1

0.1

 PR

 

176

18.1

 SD

 

610

60.0

 PD

 

188

19.3

Severe gastrointestinal toxicity

964

80

8.3

Severe hematological toxicity

969

  

 Anemia

944

29

3.1

 Neutropenia

935

115

12.3

 Thrombocytopenia

950

34

3.6

Median Time to outcomes (month)

972

  

 PFS

 

896

9.1

 OS

 

972

19.3

  1. ECOG PS, Eastern Cooperative Oncology Group performance status; TNM, tumor-node metastasis; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival (months); OS, overall survival (months).
  2. aOther carcinomas included mixed cell or undifferentiated carcinoma.
  3. bNonsmokers were defined as those who had smoked <1 cigarette per day and for <1 year in their lifetime.
Back to article page